B7-H4 Further Stratifies Patients With Endometrial Cancer Exhibiting a Nonspecific Molecular Profile
Authors:
Open Access
- 20 January 2023
- journal article
- research article
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 147 (11) , 1288-1297
Abstract
Context.—: Endometrial cancer is classified into 4 molecular subtypes: DNA polymerase epsilon ultramutated, mismatch repair deficient, p53 mutant, and nonspecific molecular profile (NSMP). Additional biomarkers are urgently needed to better characterize the NSMP subtype, the largest group with heterogeneous pathologic features and prognoses. Objective.—: To investigate the expression of B7 homolog 3 (B7-H3), B7 homolog 4 (B7-H4), and V-set and immunoglobulin domain containing 3 (VSIG-3, a ligand for B7-H5) in 833 patients with endometrial cancer and determine their associations with clinicopathologic and molecular features as well as survival outcomes. Design.—: Molecular classification was determined by polymerase epsilon sequencing and immunohistochemical staining for p53 and mismatch repair proteins. B7-H3, B7-H4, VSIG-3, and programmed death ligand-1 (PD-L1) were detected via immunohistochemistry. Results.—: The positivity rates for B7-H3 in each of the tumor and immune cells, B7-H4 (exclusively in tumor cells), and VSIG-3 (exclusively in tumor cells) were 89.0%, 42.3%, 71.5%, and 99.8%, respectively. B7-H3 and B7-H4 positivity in tumor cells was associated with favorable pathologic features and prognosis. In contrast, B7-H3 expression in immune cells was frequent in samples with unfavorable pathologic features; those with p53-mutant subtype, PD-L1 positivity, and a high density of CD8+ T cells; and in patients with poor prognoses. Positive B7-H4 expression was a predictor of improved survival in patients with the NSMP subtype independent of tumor stage or pathologic features. Conclusions.—: The NSMP subgroup of endometrial cancer can be further stratified by B7-H4 status. Incorporating B7-H4 status into the molecular classification of NSMP could improve the ability to predict disease relapse.Keywords
This publication has 42 references indexed in Scilit:
- Effects of B7-H3 expression on tumour-infiltrating immune cells and clinicopathological characteristics in non–small-cell lung cancerEuropean Journal of Cancer, 2020
- Expression of the immune checkpoint VISTA in breast cancerCancer Immunology, Immunotherapy, 2020
- B7H4 expression in tumor cells impairs CD8 T cell responses and tumor immunityCancer Immunology, Immunotherapy, 2019
- VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancerCancer Immunology, Immunotherapy, 2019
- Structure and Functional Binding Epitope of V-domain Ig Suppressor of T Cell ActivationCell Reports, 2019
- Co-inhibitory Molecule B7 Superfamily Member 1 Expressed by Tumor-Infiltrating Myeloid Cells Induces Dysfunction of Anti-tumor CD8+ T CellsImmunity, 2018
- Higher preoperative serum levels of PD‐L1 and B7‐H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF‐targeted therapy and unfavorable prognosis of renal cell carcinomaCancer Medicine, 2016
- B7‐H3‐mediated tumor immunology: Friend or foe?International Journal of Cancer, 2013
- B7-H4 expression associates with cancer progression and predicts patient’s survival in human esophageal squamous cell carcinomaCancer Immunology, Immunotherapy, 2011
- BT‐IgSF, a novel immunoglobulin superfamily protein, functions as a cell adhesion moleculeJournal of Cellular Physiology, 2005